CLSD - Clearside Biomedical Inc Stock Price, Fair Value and News

$0.87-0.06 (-6.45%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CLSD Price Action

Last 7 days

-14.7%

Last 30 days

-17.1%

Last 90 days

-33.6%

Trailing 12 Months

-16.3%

CLSD RSI Chart

CLSD Valuation

Market Cap

66.0M

Price/Earnings (Trailing)

-2.07

Price/Sales (Trailing)

8.57

Price/Free Cashflow

-3.37

CLSD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CLSD Fundamentals

CLSD Revenue

Revenue (TTM)

7.7M

Rev. Growth (Yr)

20.84%

Rev. Growth (Qtr)

1.1K%

CLSD Earnings

Earnings (TTM)

-31.9M

Earnings Growth (Yr)

17.04%

Earnings Growth (Qtr)

-1.22%

CLSD Profitability

Return on Equity

91.63%

Return on Assets

-109.32%

Free Cashflow Yield

-29.71%

CLSD Investor Care

Shares Dilution (1Y)

21.53%

Diluted EPS (TTM)

-0.45

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.5M	7.5M	7.7M	0
2023	0	2.0M	2.5M	8.6M
2022	22.5M	15.5M	8.4M	1.3M
2021	13.3M	18.7M	24.2M	29.6M
2020	6.2M	6.5M	9.8M	7.9M
2019	565.8K	1.1M	1.6M	2.2M
2018	0	0	0	30.0K
2017	476.3K	432.5K	388.8K	345.0K
2016	0	0	0	520.0K
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CEO	Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
WEBSITE	https://clearsidebio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	36

Clearside Biomedical Inc Frequently Asked Questions

What is the ticker symbol for Clearside Biomedical Inc? What does CLSD stand for in stocks?

CLSD is the stock ticker symbol of Clearside Biomedical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Clearside Biomedical Inc (CLSD)?

As of Fri Dec 20 2024, market cap of Clearside Biomedical Inc is 65.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLSD stock?

You can check CLSD's fair value in chart for subscribers.

Is Clearside Biomedical Inc a good stock to buy?

The fair value guage provides a quick view whether CLSD is over valued or under valued. Whether Clearside Biomedical Inc is cheap or expensive depends on the assumptions which impact Clearside Biomedical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLSD.

What is Clearside Biomedical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, CLSD's PE ratio (Price to Earnings) is -2.07 and Price to Sales (PS) ratio is 8.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLSD PE ratio will change depending on the future growth rate expectations of investors.